The Rest Of Asia Pacific Periodontal Disease Treatment Market was valued at $39.49 Million in 2024 and projected to reach to $60.17 Million by 2029, representing a compound annual growth rate of 7.3%. The Rest Of Asia Pacific periodontal disease treatment market is positioned for substantial growth through 2029, driven by escalating disease prevalence and healthcare infrastructure development across emerging economies in the region.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Asia Pacific periodontal disease treatment market valued at USD 39.49 million in 2024, expanding to USD 60.17 million by 2029, representing 52.4% absolute growth over the forecast period.
Rest Of Asia Pacific exhibits 7.3% CAGR, significantly outpacing the global benchmark of 5.9%, indicating accelerated market momentum and stronger regional adoption of periodontal treatments.
Increasing periodontal disease incidence across Rest Of Asia Pacific nations driven by lifestyle changes, dietary patterns, and aging populations, creating sustained demand for treatment solutions.
Growing healthcare expenditure and improved oral health awareness in Rest Of Asia Pacific countries are catalyzing market expansion and accessibility to advanced periodontal treatment modalities.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | AGGRESSIVE PERIODONTITIS (Disease) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 5.9% from 2024 to 2029 |
| Largest Segment | NON-SURGICAL TREATMENT (Treatment) |
| Market Size Base Year (Billions) | ~USD 2.57 (2024) |
| Revenue Forecast (Billions) | ~USD 3.43 (2029) |
| Segments Covered | Product, Disease, Type, Treatment |
4 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| DENTSPLY SIRONA | United States | Public Company | Connected Technology Solutions,Essential Dental Solutions,Orthodontic and Implant Solutions, |
| ENVISTA HOLDINGS CORPORATION | United States | Public Company | Specialty Products & Technologies – Implants & Biomaterials,Specialty Products & Technologies – Orthodontics & Clear Aligners,Equipment & Consumables – Imaging, Software & Visualization, |
| HENRY SCHEIN, INC. | United States | Public Company | Global Distribution and Value-Added Services,Global Specialty Products,Global Technology, |
| BIOLASE, INC. | United States | Public Company | Waterlase all-tissue systems,Diode soft-tissue systems,Consumables, fibers, and handpieces, |
| NAKANISHI INC. | Japan | Public Company | Dental handpieces (air turbines, contra-angles, micromotors),Surgical and mobile dentistry systems,Dental lab, hygiene, and maintenance products, |
| A-DEC INC. | Switzerland | Public Company | Flexible placement (temporary staffing and contracting),Permanent placement and career transition,Outsourcing and engineering consulting, |
DENTSPLY SIRONA is a United States-based public company founded in 1877 with 14,000 employees. The company operates in the dental industry.
ENVISTA HOLDINGS CORPORATION is a United States-based public company founded in 2018 with 12,000 employees. The company operates in the dental industry.
HENRY SCHEIN, INC. is a United States-based public company founded in 1932 with 25,000 employees. The company operates in the dental industry.
BIOLASE, INC. is a United States-based public company founded in 1984 with 157 employees. The company operates in the dental industry.
NAKANISHI INC. is a Japan-based public company founded in 1930 with 2,204 employees. The company operates in the dental industry.
A-DEC INC. is a Switzerland-based public company founded in 1957 with 33,569 employees. The company operates in the dental industry.
Rest Of Asia Pacific's periodontal disease treatment market was valued at USD 39.49 million in 2024.
Rest Of Asia Pacific's periodontal disease treatment market is forecast to reach USD 60.17 million by 2029.
Rest Of Asia Pacific's periodontal disease treatment market is expected to grow at a compound annual growth rate of 7.3% from 2024 to 2029.
Rest Of Asia Pacific's CAGR of 7.3% exceeds the global market CAGR of 5.9%, demonstrating stronger regional growth momentum.
Rest Of Asia Pacific's market growth is driven by rising periodontal disease prevalence, expanding healthcare infrastructure, increasing oral health awareness, and growing adoption of advanced treatment technologies.
Full forecast, segment splits, and company analysis for all Periodontal Disease Treatment Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report